Have patients with esophagitis got an increased risk of adenocarcinoma? Results from a population-based study

Table 1 SNOMED diagnostic codes used in study

Code	Diagnostic term	Number of patients
M40000	Inflammation	777
MZ0005	Non-specific inflammation	9
M40005	Active inflammation	88
M41000	Acute inflammation	31
M42100	Active chronic inflammation	62
M43000	Chronic inflammation	279
M76820	Inflammatory polyp	2
M36500	Edema	2
M36100	Congestion	52
M45020	Granulation tissue	11
M14110	Erosion	6
M38000	Ulcer/ulceration	570
MY0102	Reflux esophagitis	125

Table 2 Risk of esophageal and lung cancer in patients with histologically confirmed esophagitis and without Barrett’s esophagus

		Number ofcases	Incidence per 100 person-years of follow-up (95%CI)	Expected numberof cases	Standardized incidenceratio (95%CI)
OAC	All patients	0	-	1.35	0 ( -, 2.73)1
All esophageal cancers	All patients	9	0.07 (0.04, 0.14)	3.29	2.73 (1.25-5.19)
	Men	4	0.06 (0.02, 0.16)	1.8	2.22 (0.61-5.69)
	Women	5	0.07 (0.02, 0.17)	1.43	3.49 (1.14-8.16)
Esophageal	All patients	3	0.02 (0.01, 0.07)	1.02	2.93 (0.61-8.59)
SCC
	Men	1	0.02 (0, 0.10)	0.44	2.28 (0.06-12.6)
	Women	2	0.03 (0, 0.12)	0.59	3.40 (0.41-12.2)
Lung cancer	All patients	21	0.16 (0.10, 0.24)	19.71	1.07 (0.66-1.63)
	Men	16	0.25 (0.14, 0.40)	11.36	1.41 (0.81-2.29)
	Women	5	0.07 (0.02, 0.17)	7.63	0.66 (0.21-1.53)
Sensitivity analyses
Reclassified OAC2	All patients	6	0.04 (0.01, 0.13)	2.27	2.64 (0.97-5.75)
	Men	3	0.05 (0.02, 0.11)	1.36	2.20 (0.45-6.45)
	Women	3	0.04 (0.01, 0.13)	0.85	3.54 (0.73-10.31)
Reclassified esophageal SCC3	All patients	9	0.07 (0.02, 0.17)	1.94	4.64 (2.12-8.81)
	Men	4	0.06 (0.02, 0.16)	0.91	4.39 (1.20-11.25)
	Women	5	0.07 (0.02, 0.17)	1.02	4.92 (1.59-11.44)

¹One-sided 97.5%CI;

²OAC+histologically unspecified cancers;

³SCC+histologically unspecified cancers.